Atrium Therapeutics, Inc. (RNA)
About Atrium Therapeutics, Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $19.6M
- Net income
- -$16.6M
- Total assets
- $292.4M
- Market cap
- $201.8M
- Operating margin
- -3977.3%
- Net margin
- -3650.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $18.8M
- Operating expenses
- $764.7M
- Operating income
- -$745.9M
- Income tax
- $0
- Net income
- -$684.6M
- EPS (basic)
- $-4.97
- EPS (diluted)
- $-4.97
Balance sheet
- Total assets
- $2.0B
- Current assets
- $1.8B
- Total liabilities
- $269.4M
- Current liabilities
- $195.4M
- Shareholders’ equity
- $1.7B
Cash flow
- Operating cash flow
- -$650.4M
- Investing cash flow
- -$38.0M
- Financing cash flow
- $851.0M
- Net cash flow
- $162.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $201.8M
- EPS (diluted)
- $-4.97
- Shares outstanding
- 17.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 27, 2026
Atrium Therapeutics, Inc. (RNA) Stock Price
- Reported a net loss of $16.6M in FY2026.
- Revenue grew 176% from FY2020 to FY2025.
- Trading 84% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Atrium Therapeutics, Inc..
Write a review
News about Atrium Therapeutics, Inc.
News & sentiment via Polygon.io
Atrium Therapeutics, Inc.: frequently asked questions
Is Atrium Therapeutics, Inc. an American company?
Atrium Therapeutics, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Atrium Therapeutics, Inc. headquartered?
Atrium Therapeutics, Inc. is headquartered in San Diego, California, United States.
Is Atrium Therapeutics, Inc. publicly traded?
Yes — Atrium Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol RNA on the NASDAQ.
What does Atrium Therapeutics, Inc. do?
Atrium Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
